Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Acute Leukemia ALL: Cellular, antibody and targeted therapy

Cellular, antibody and targeted therapy

 
Xinxin Wang, Shiqi Li, Lei Gao, et al.
 
The authors of the abstract conclude: 
GC027 shows promising efficacy treating adult r/r T-ALL. With a single infusion of GC027, 80% of patients had robust CAR-T cell expansion and achieved a durable MRD- CR (161 days and response still ongoing) without using any biologics as part of the preconditioning therapy or bridging to HSCT. GC027 has demonstrated superior clinical efficacy and induced deep response in patients with acceptable safety profile. The trial is ongoing and updated data will be presented at the meeting.  
————————————————————————————————————————————————————————
 
 
Elias Jabbour, Vinod A. Pullarkat, Norman J. Lacayo, et al.
 
The authors of the abstract conclude: 
Ven+Nav with chemotherapy is well-tolerated, and efficacy is promising in heavily pretreated pts (including those with prior blinatumomab, inotuzumab, or CAR-T) with high rates of CR/CRi/CRp. Clinical follow-up, correlative biomarker analysis, and expansion cohort enrollment to assess discontinuous dosing are underway.————————————————————————————————————————————————————————
 
 
Anthony Moorman, Claire Schwab, Amy Kirkwood, et al.
 
The authors of the abstract conclude: 
ABL-class fusions are frequent among BCP-ALL and T-ALL patients who respond slowly to induction therapy. In this study, ABL-class patients were essentially randomly assigned to receive a TKI in first remission. Preliminary results from this small cohort support the concept that adding TKI to chemotherapy improves the outcome of these high-risk patients but longer follow-up is necessary.
————————————————————————————————————————————————————————
 
 
Andre Baruchel, Joerg Krueger, Adriana Balduzzi, et al.
 
The authors of the abstract conclude: 
Efficacy and safety of tisagenlecleucel in the B2001X study remain consistent with outcomes in ELIANA. In patients with INO as bridging therapy, a trend toward suboptimal expansion was observed. In patients with prior BLINA or INO as bridging therapy, a trend toward suboptimal outcomes was observed. These observations should be interpreted with caution due to small numbers, short follow-up, and potential confounding factors.
————————————————————————————————————————————————————————
 
 
Claire Roddie, Maeve O’Reilly, Maria Marzolini, et al.
 
The authors of the abstract conclude: 
AUTO1 has a tolerable safey profile in adult patients with r/r B-ALL despite high disease burden. Early data shows high remission rates with 87% achieving MRD negative CR and in patients treated with the closed process, the EFS at 6months is 100%. This preliminary data supports the further development of AUTO1 as a stand-alone treatment in patients with r/r B-ALL. Data from addiitonal patients and more follow up will be presented.